Astrazeneca Plc $AZN Shares Sold by Cohen Investment Advisors LLC

Cohen Investment Advisors LLC cut its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 50.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,557 shares of the company’s stock after selling 3,618 shares during the quarter. Cohen Investment Advisors LLC’s holdings in Astrazeneca were worth $689,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Triumph Capital Management acquired a new stake in Astrazeneca in the third quarter valued at $25,000. MV Capital Management Inc. acquired a new position in Astrazeneca during the 4th quarter worth $26,000. Bangor Savings Bank increased its position in shares of Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares during the last quarter. Eagle Bay Advisors LLC bought a new stake in shares of Astrazeneca in the 4th quarter worth about $30,000. Finally, YANKCOM Partnership acquired a new stake in shares of Astrazeneca in the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Stock Up 1.2%

AZN stock opened at $192.53 on Tuesday. The firm’s 50-day moving average is $183.97 and its two-hundred day moving average is $188.38. The company has a market capitalization of $298.59 billion, a price-to-earnings ratio of 28.91, a price-to-earnings-growth ratio of 1.58 and a beta of 0.24. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, analysts forecast that Astrazeneca Plc will post 10.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AZN has been the topic of several research analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Fourteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.